GL1X · GenesisL1 explorer

Research workbench

Structure-based drug design and structural biology study of novel nonpeptide inhibitors of SARS-cov main protease

Analyse Structure-based drug design and structural biology study of novel nonpeptide… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
2GZ8
Type
protein
Length
306 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Replicase polyprotein 1AB
EC
3.4.22.-
UniProt
P59641
Ligands
F3F
Pockets
2 · best druggability 0.52

Structure

x-ray diffraction · 1 distinct chain · 25% helix, 29% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AReplicase polyprotein 1AB (EC 3.4.22.-)protein30625% helix, 29% strandP59641

Ligands and binding sites

  • F3F · S-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl] 5-(phenylethynyl)furan-2-carbothioate · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12260.520.7727F3F
21190.400.7525empty

Compared structures

  • 2GZ8 · Structure-Based Drug Design and Structural Biology Study of Novel Nonpeptide Inhibitors… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.